The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season.

U.S. Health Secretary Robert F. Kennedy Jr.'s surprise ouster of a national vaccine advisory board, claiming it was "plagued ...

Seven of those fired had received up to US$55,000 from drugmakers. Read more at straitstimes.com. Read more at ...

In this week’s edition of InnovationRx, we look at RFK Jr.’s vaccine advisory committee purge, a tech billionaire’s funding ...

Merck & Co., Inc. (NYSE:MRK) is one of the best wide moat stocks to buy now. On June 9, Merck’s preventative antibody shot ...

The FDA has approved Merck’s Enflonasia, a monoclonal antibody designed to prevent respiratory syncytial virus lower respiratory tract disease in newborns and infants. The approval is based on data ...

CHARLOTTE — The Food and Drug Administration approved a new vaccine to help protect infants from RSV on Monday. The treatment ...

WASHINGTON – The Food and Drug Administration has approved a new monoclonal antibody to protect infants from RSV. The ...

RSV monoclonal antibody, clesrovimab,” which was approved by the FDA yesterday, Leerink Partners LLC analyst Daina Graybosch said. Insmed Inc.’s chair and CEO, Will Lewis, called the phase IIb trial ...

Merck scored a major win with FDA approval for Enflonsia, its fresh RSV-fighting antibody aimed at shielding infants. This ...

Financial disclosure records show that members of the vaccine safety panel fired by HHS Secretary RFK Jr. had financial ties to the pharmaceutical industry.